Context Ebit from 2010 to 2024
| CNTX Stock | USD 1.39 0.05 3.47% |
EBIT | First Reported 2010-12-31 | Previous Quarter -25.1 M | Current Value -26.3 M | Quarterly Volatility 12.2 M |
Check Context Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Context Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 435.1 K, Selling General Administrative of 9.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.6. Context financial statements analysis is a perfect complement when working with Context Therapeutics Valuation or Volatility modules.
Context | Ebit |
Latest Context Therapeutics' Ebit Growth Pattern
Below is the plot of the Ebit of Context Therapeutics over the last few years. It is Context Therapeutics' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Context Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
Context Ebit Regression Statistics
| Arithmetic Mean | (22,911,416) | |
| Coefficient Of Variation | (53.41) | |
| Mean Deviation | 10,527,560 | |
| Median | (26,326,247) | |
| Standard Deviation | 12,236,722 | |
| Sample Variance | 149.7T | |
| Range | 30.7M | |
| R-Value | 0.61 | |
| Mean Square Error | 101.1T | |
| R-Squared | 0.37 | |
| Significance | 0.02 | |
| Slope | 1,671,318 | |
| Total Sum of Squares | 2096.3T |
Context Ebit History
Other Fundumenentals of Context Therapeutics
About Context Therapeutics Financial Statements
Context Therapeutics investors use historical fundamental indicators, such as Context Therapeutics' Ebit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Context Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBIT | -25.1 M | -26.3 M | |
| EBITDA | -25.1 M | -23.8 M | |
| Ebt Per Ebit | 0.96 | 1.00 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Context Stock Analysis
When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.